Journals / Dicle Tıp Dergisi / 2019 / Cilt: 46 - Sayı: 4

Post-Transplant Lymphoproliferative Diseases After Solid Organ Transplantation: Single Center Experience

Solid Organ Transplantasyonu Sonrası Post-Transplant Lenfoproliferatif Hastalıklar: Tek Merkez Deneyimi

Pages
743–749
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Age of patients, age of transplantation, age of diagnosis of lymphoproliferative disease, time until diagnosis of lymphoproliferative disease after transplantation, clinical presentations for lymphoproliferative disease, tumor characteristics, lactate dehydrogenase levels at diagnosis, immunosuppressive therapies, treatments for lymphoproliferative disease and their responses to these therapies, overall and progression free survival were evaluated.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: We aimed to evaluate the clinical findings, laboratory features, general and progression free survival of the patients diagnosed with post-transplant lymphoproliferative disease in our clinic.
📊
Key Findings & Data:Method: Patients who were diagnosed with post-transplant lymphoproliferative disease after solid organ transplantation between January 2000 and December 2018 were retrospectively analysed.
💡
Conclusion & Impact:Age of patients, age of transplantation, age of diagnosis of lymphoproliferative disease, time until diagnosis of lymphoproliferative disease after transplantation, clinical presentations for lymphoproliferative disease, tumor characteristics, lactate dehydrogenase levels at diagnosis, immunosuppressive therapies, treatments for lymphoproliferative disease and their responses to these therapies, overall and progression free survival were evaluated.
🔬Design:Research Article
📍Scope:2000 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: We aimed to evaluate the clinical findings, laboratory features, general and progression free survival of the patients diagnosed with post-transplant lymphoproliferative disease in our clinic. Method: Patients who were diagnosed with post-transplant lymphoproliferative disease after solid organ transplantation between January 2000 and December 2018 were retrospectively analysed. Age of patients, age of transplantation, age of diagnosis of lymphoproliferative disease, time until diagnosis of lymphoproliferative disease after transplantation, clinical presentations for lymphoproliferative disease, tumor characteristics, lactate dehydrogenase levels at diagnosis, immunosuppressive therapies, treatments for lymphoproliferative disease and their responses to these therapies, overall and progression free survival were evaluated. Results: 10 patients were diagnosed with post-transplant lymphoproliferative disease in our clinic. Eight of the patients were diagnosed as lymphoproliferative disease after kidney transplantation and 2 patients after liver transplantation. 8 patients were diagnosed with diffuse large B-cell lymphoma, 2 patients were diagnosed with Hodgkin's lymphoma 3 times (1 patient relapsed). 5-year survival was 90 ± 9% and event-free survival was 150.76 ± 13.28 months. Conclusion: Patients are in remission and alive except one patient who died because of septic complications in early transplant period. The 5-year survival rate of our study is longer than the many studies reported in the literature and it shows the success of the treatment.

Özet

Amaç: Kliniğimizde solid organ transplantasyonu sonrası post-transplant lenfoproliferatif hastalık tanısı almış hastaların klinik bulgularını, laboratuar özelliklerini, genel ve progesyonsuz sağ kalımlarını değerlendirmeyi amaçladık. Yöntemler: Ocak 2000- Aralık 2018 yılları arasında solid organ transplantasynu sonrası post-transplant lenfoproliferatif hastalık tanısı alan hastalar retrospektif olarak incelendi. Hastaların cinsiyeti, transplantasyon oldukları yaş, lenfoproliferatif hastalık tanı yaşı, transplantasyon sonrası lenfoproliferatif hastalık tanısına kadar geçen süre, lenfoproliferatif hastalık için klinik prezentasyonları, tümör karakteristikleri, tanı anındaki laktat dehidrogenaz düzeyleri, immunsupresif tedavileri, lenfoproliferatif hastalık için aldıkları tedaviler ve bu tedavilere yanıtları, toplam ve olaysız sağ kalım değerlendirildi. Bulgular: On hastaya post-transplant lenfoproliferatif hastalık tanısı konmuştur. Hastaların 8’i böbrek, 2’si karaciğer transplantasyonu sonrası lenfoproliferatif hastalık tanısı almışlardır. 8 hastaya diffüz büyük B hücreli lenfoma, 2 hastaya toplam 3 kere Hodgkin lenfoma (1 hasta nüks etmiştir) tanısı konmuştur. 5 yıllık sağ kalım %90±9 ve olaysız sağ kalım 150,76±13,28 ay bulunmuştur. Sonuç: Erken dönemde septik nedenlerle kaybedilen bir hasta dışındaki hastalar hayatta ve remisyondadır. Çalışmamızın 5 yıllık sağ kalım oranının literatürde bildirilen birçok çalışmadan daha uzun olması tedavi başarısını göstermektedir.

🔖

Cite This Article

DAVULCU, E. A., BÜlBÜL, H., ULUSOY, Y., SOYER, N. A., DEMİR, D., ÖZSAN, N., AK, G., ŞAHİN, F., TÖBÜ, M., TOMBULOĞLU, M., VURAL, F., SAYDAM, G. (2019). Post-Transplant Lymphoproliferative Diseases After Solid Organ Transplantation: Single Center Experience. Dicle Tıp Dergisi, Cilt: 46 - Sayı: 4, 743–749. https://ajindex.com/articles/173341

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Adami J, Gäbel H, Lindelöf B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003; 89: 1221
  2. Petrara MR, Giunco S, Serraino D, Dolcetti R, De Rossi A. Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesis-driven treatment. Cancer Lett 2015; 369: 37-44
  3. Ibrahim HA, Naresh KN. Posttransplant lymphoproliferative disorders. Adv Hematol 2012; 2012: 230173
  4. Opelz G, Naujokat C, Daniel V, Terness P, Döhler B. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 2006; 81: 1227
  5. Shahinian VB, Muirhead N, Jevnikar AM, et al. EpsteinBarr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients. Transplantation 2003; 75: 851
  6. Zangwill SD, Hsu DT, Kichuk MR, et all. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients. J Heart Lung Transplant 1998; 17: 1161
  7. Swerdlow SH, Campo E, Harris NL, et al. (Eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition). lARC: Lyon 2017, p.453- 462
  8. Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001; 71: 1076
  9. Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012; 13: 196-206
  10. Jagadeesh D, Woda BA, Draper J, Evens AM. Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. Curr Treat Options Oncol 2012; 13: 122
  11. Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 2010; 20; 28: 1038-46
  12. Dierickx D, Tousseyn T, Sagaert X, et al. Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors. Leuk Lymphoma 2013; 54: 2433-40
  13. Kinch A, Baeckl